Dasatinib Monohydrate: A Multitargeted ABL Kinase Inhibitor for CML Research

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a clinically approved, multitargeted tyrosine kinase inhibitor with nanomolar potency against ABL, SRC, KIT, and PDGFR kinases (APExBIO). It is effective against both wild-type and imatinib-resistant BCR-ABL isoforms, making it a standard in chronic myeloid leukemia (CML) and Ph-positive acute lymphoblastic leukemia (ALL) research (Telerman et al., 2022). Dasatinib demonstrates antiproliferative effects across hematological and solid tumor cell lines in vitro, and inhibits disease progression in BCR-ABL-driven mouse models in vivo. Its biophysical profile includes a molecular weight of 506.02 and solubility of ≥25.3 mg/mL in DMSO, but insolubility in ethanol and water. Dasatinib has been FDA-approved since 2006 for Ph-positive leukemias, facilitating both mechanistic studies and translational applications in kinase-driven diseases.

Biological Rationale

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, resulting from a t(9;22)(q34;q11) translocation that creates the BCR-ABL fusion gene encoding a constitutively active tyrosine kinase (Telerman et al., 2022). This kinase drives uncontrolled proliferation and resistance to apoptosis in hematopoietic progenitors. Targeting this aberrant signaling is the core therapeutic strategy for CML and Ph-positive ALL (see related review). Resistance to first-line ABL kinase inhibitors such as imatinib frequently emerges through point mutations in the BCR-ABL domain or activation of alternative kinase pathways. Dasatinib Monohydrate, by inhibiting both ABL and off-target kinases (including SRC, KIT, and PDGFR), provides a robust tool for dissecting kinase networks and overcoming resistance mechanisms in CML and related diseases.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate is an ATP-competitive, multitargeted tyrosine kinase inhibitor. It binds to the active and inactive conformations of the ABL kinase domain, inhibiting downstream signaling required for cell proliferation and survival. In vitro, Dasatinib inhibits BCR-ABL with an IC₅₀ of 3.0 nM, and SRC family kinases with an IC₅₀ of 0.55 nM (DMSO, 25°C, enzyme assay conditions; APExBIO). The compound also suppresses KIT, PDGFR, and several other kinases implicated in oncogenesis and resistance. By targeting both BCR-ABL and SRC, Dasatinib overcomes imatinib-resistant mutations (except T315I) and inhibits proliferation in a range of CML model systems. Dasatinib’s multitargeted profile is particularly relevant for studying cross-talk and redundancy in kinase signaling pathways.

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL kinase activity with an IC₅₀ of 3.0 nM under cell-free conditions (enzyme assay, 25°C, DMSO buffer; APExBIO).
• It inhibits SRC family kinases with an IC₅₀ of 0.55 nM (enzyme, DMSO, 25°C; APExBIO).
• Shows broad antiproliferative effects in vitro on CML and solid tumor cell lines at nanomolar concentrations (cell viability, 24–72h, DMSO vehicle; Dasatinib Monohydrate: Potent ABL Kinase Inhibition).
• Dasatinib reduces disease progression and bioluminescent tumor burden in BCR-ABL-driven mouse models (in vivo, 25 mg/kg oral gavage, daily, 3–4 weeks; Dasatinib Monohydrate: Advanced Workflows in CML).
• FDA-approved since 2006 for all Ph-positive CML phases and Ph+ ALL, supporting its clinical and research utility (FDA).
• Dasatinib impacts neutrophil extracellular trap (NET) formation in CML, a pathway recently implicated in vascular toxicity and disease biology (Telerman et al., 2022).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is widely used for:

• Modeling imatinib-resistant BCR-ABL variants in CML and ALL research.
• Interrogating SRC, KIT, PDGFR, and off-target kinase pathways in tumor biology.
• Studying neutrophil extracellular trap (NET) biology and kinase-driven vascular events (Telerman et al., 2022).
• Preclinical validation of multitargeted kinase inhibition in assembloid and patient-derived xenograft models (see translational perspectives—this article extends mechanistic detail to NET formation and vascular toxicity).
• Screening kinase pathway dependencies in both hematological and solid tumor contexts (see tumor assembloid protocols—our present review clarifies best practices for kinase selectivity analysis).

Common Pitfalls or Misconceptions

• Dasatinib does not inhibit the T315I BCR-ABL mutation; alternative agents are required (APExBIO).
• It is insoluble in ethanol and water; DMSO is the required solvent for in vitro work.
• Long-term storage of Dasatinib in solution reduces potency; prepare fresh aliquots and store at -20°C for short-term use.
• Not all off-target effects are beneficial; multitargeted inhibition may complicate interpretation in signaling studies—controls are essential.
• Clinical cardiovascular risks may not be apparent in all preclinical models; NET formation and vascular toxicity should be monitored (Telerman et al., 2022).

Workflow Integration & Parameters

Product Format: Dasatinib Monohydrate (B5954; APExBIO) is supplied as a solid (molecular weight 506.02; C₂₂H₂₈ClN₇O₃S). For experimental use, dissolve at ≥25.3 mg/mL in DMSO. Do not use ethanol or water as solvents.

Recommended Storage: Store powder and solutions at -20°C. Use fresh solutions for maximal stability and reproducibility.

Experimental Parameters: In vitro, effective concentrations range from 1–100 nM (cell culture, 24–72h, DMSO vehicle, 37°C, 5% CO₂). For in vivo mouse studies, oral gavage at 25 mg/kg daily for up to 4 weeks is standard (refer to published protocols for model-specific adjustments).

Controls: Always include DMSO-only controls and, where relevant, imatinib or nilotinib comparators to distinguish ABL-specific from off-target effects. Monitor for NET formation and cardiotoxicity in long-term studies.

Integration with Advanced Workflows: Dasatinib Monohydrate is compatible with assembloid, organoid, and patient-derived xenograft platforms for investigating kinase network redundancies and resistance (see advanced workflows).

For additional detail and ordering, see the Dasatinib Monohydrate product page (APExBIO).

Conclusion & Outlook

Dasatinib Monohydrate is a cornerstone reagent for dissecting kinase signaling and resistance in CML, Ph+ ALL, and kinase-driven solid tumors. Its high potency, broad kinase selectivity, and efficacy against imatinib-resistant forms make it indispensable for both mechanistic and translational research. Recent studies implicate its role not only in leukemia inhibition but also in modulating neutrophil extracellular trap (NET) formation and vascular toxicity, highlighting the importance of comprehensive experimental design (Telerman et al., 2022). As kinase pathway mapping and resistance mechanisms grow in complexity, Dasatinib Monohydrate—supplied by APExBIO—remains a validated, versatile tool for the next generation of cancer research and drug development.